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THE IMPACT OF 
IMPLANTABLE 
CARDIOVERTER- 
DEFIBRILLATORS ON 
MORTALITY AMONG 
PATIENTS ON THE WAITING 
LIST FOR HEART 
TRANSPLANTATION 
Implantable cardioverter-defibrillators were investigated for their impact 
on mortality in 228 consecutive heart transplant candidates on the waiting 
list for transplantation (207 patients without and 21 with implantable 
cardioverter-defibrillator therapy). The mortality rate in 207 patients 
without implantable cardioverter-defibrillator therapy was 23.2% and in 21 
patients with implantable cardioverter-defibrillator therapy was 4.7%. In a 
Cox proportional hazards model for all 228 study patients (mortality while 
on the waiting list: 21.5%; transplantation rate: 54.8%), the absence of an 
implantable cardioverter-defibrillator was only a marginally significant 
predictor of mortality (p = 0.079). However, the absence of an implantable 
cardioverter-defibrillator was a powerful predictor of mortality for a 
subgroup of 134 patients with high-grade ventricular arrhythmias on 
Holter electrocardiography (mortality while on the waiting list: 26.1%; 
transplantation rate: 54.5%; p = 0.022) and for a subgroup of 58 survivors 
of sudden cardiac death (mortality while on the waiting list: 22.4%; 
transplantation rate: 56.9%; p = 0.018). Implantable cardioverter-defibril- 
lator therapy can be strongly recommended in transplant candidates with 
a history of sudden cardiac death. Recommendations for an expanded, 
prophylactic use of implantable cardioverter-defibrillator therapy in heart 
transplant candidates cannot be given. (J THORAC CARDIOVASC SURG 1995; 
110:532-9) 
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p atients with severe heart failure who are regis- 
tered for heart transplantation face a high risk of 
death from sudden cardiac death while on the 
waiting list, mainly because of ventricular tachy- 
arrhythmias. 1-3A recent multicenter trial showed 
that more than 40% of all deaths in patients on the 
waiting list are sudden in nature. 1
Implantable cardioverter-defibrillators (ICDs) 
were shown to reduce cardiac mortality in patients 
with impaired left ventricular function by prevention 
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of sudden cardiac death. 4 In patients with an ejec- 
tion fraction less than 30%, ICD therapy resulted in 
a 5-year actuarial freedom from sudden cardiac 
death of 89.9%. 5Availability of transvenous systems 
with biphasic shock delivery is a major advantage for 
the safety of this technique, 6 and low surgical mor- 
tality at implantation and efficacy of ICD therapy in 
a series of transplant candidates were recently 
shown.7, 8These encouraging data and the difficulty 
in identifying those particular transplant candidates 
who are at risk for sudden cardiac death while on 
the waiting list 9 have stimulated the discussion 
about an expanded use of ICD therapy as a prophy- 
lactic bridge to heart transplantation. However, 
general prophylactic ICD therapy with an approxi- 
mately $40,000 device in all patients registered for 
transplantation would cause an enormous burden 
on health care resources? 
The aim of this study was to investigate by a Cox 
proportional hazards model the impact of ICD 
therapy on the mortality in patients registered 
for heart transplantation. Furthermore, the ira- 
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Table I. Baseline characteristics 
Subgroup of patients 
with high-grade 
ventricular 
arrhythmias on Subgroup of survivors of 
All study patients Holter ECG sudden cardiac death Patients with ICD 
(n = 228) (n = 134) (n = 58) therapy (n = 21) 
ICD therapy (%) 21 (9.2) 21 (15.7) 21 (36.2) 21 (100) 
Age (yr) 52.7 -+ 10.6 53.2 + 10.6 55.5 +__ 9.1 53.9 + 9.7 
Sex (male:female) 198:30 117:17 50:8 18:3 
Cause of heart failure (Idiop:Isch,%) 138:90 80:34 31:27 12:9 
NYHA class 3.2 +_ 0.6 3.3 _+ 0.5 3.3 _+ 0.5 3.1 _+ 0.5 
Absence of sinus rhythm (%) 78 (34.2) 52 (38.8) 20 (34.5) 9 (40) 
LVEF (%) 16.1 _+ 6.9 15.6 _+ 5.9 15.3 + 6.5 16.7 _+ 4.2 
Cardiac index (L/min/m 2) 2.1 + 0.5 2.1 -+ 0.5* 2.2 _+ 1.7 2.3 _+ 0.4 
CVP (mm Hg) 10.6 -+ 4.5 11.4 +_ 4.6 11.1 _+ 5.0 10.7 _+ 5.7 
PVR (Wood units) 2.7 + 1.5" 2.6 + 1.4" 2.5 _ 1.7 1.8 _ 0.8 
Antiarrhythmic drug at listing (%) 25 (11)* 21 (15.8) 14 (24.6) 6 (30) 
Ventricular arrhythmia on Holter ECG (%) 134 (58,8)* 134 (100) 55 (94.8) 21 (I00) 
Values are expressed asmean value plus or minus the standard deviation oras a proportion. Idiop, Idiopathic heart failure; Isch, ischemic heart failure; NY/-/A, 
New York Heart Association; LVEF, left ventricular ejection fraction; CVP, central venous pressure; PVR, pulmonary vascular resistance. 
*p < 0.05 between patients with and without ICD therapy among all study patients and within both subgroups (for exact values ee Results ection). 
Table I I .  Fol low-up o f  patients on the waiting list 
Subgroup of patients with 
high-grade ventricular Subgroup of survivors 
All study patients arrhythmias on Holter ECG of sudden cardiac Patients with ICD 
(n = 228) (n = 134) death (n = 58) therapy (n = 21) 
Follow-up time (mo)* 11 (0.25-20) 11 (0.5-20) 11 (0.5-20) 11 (1-20) 
Waiting time to transplantation (mo)t 4 (0.25-20) 4 (0.5-20) 4 (0.5-20) 4 (1-20) 
Calculation offollow-up times and waiting times to transplantation derived from Kaplan-Meier analysis. Values are expressed asmedian and range. Starting 
point: registration the waiting list. 
*End point: still waiting at the end point of study. 
?End point: transplantation. 
pact  of  ICD therapy  was ca lcu la ted  for the sub-  
group of pat ients  wi th  h igh-grade  vent r i cu la r  ar- 
rhythmias  seen  on  Ho l te r  e lec t rocard iography  
(ECG)  and  :for the subgroup of pat ients  who had 
a l ready  had  an event  of  sudden card iac  death  
be fore  reg is t rat ion .  
Patients and methods 
Baseline characteristics and follow-up. We reviewed 
the history of 228 consecutive heart transplant candidates 
registered :by the transplant center of the University of 
Vienna, Austria, to the Eurotransplant waiting list be- 
tween March 1, 1992 (starting point of the study: on this 
date the first patient with an ICD was registered), and 
October 31, 1993 (end point of the study). The indication 
for transplantation i all patients was end-stage heart 
disease, with unacceptable prognosis for survival and unac- 
ceptable disability even after careful consideration of all 
lO other medical and surgical therapy. All baseline character- 
istics of study patients were recorded within 4 weeks before 
registration and are presented in Table I. Twenty-one out of 
the 228 patients were registered with ICD therapy, which 
was given for an event of ventricular tachyarrhythmia before 
registration that necessitated external electric defibrillation 
(median implantation time of the ICDs before registration: 6 
months, range from 0.25 to 84 months). 
While on the waiting list all patients were monitored 
clinically with comparable intensity. ICD function was 
monitored with respect to adequate discharges; ICD 
discharges were counted during follow-up while the pa- 
tient was on the waiting list. At the time of registration for 
transplantation patients were treated with angiotensin- 
converting enzyme inhibitors (94.7%), digitalis (93.8%), 
diuretics (95.2%), antiarrhythmic drugs (11%; amioda- 
rone n = 23 and sotalol n = 22), and permanent antico- 
agulation therapy (77.5%). Intravenous catecholamines 
were administered in 11.5% and prostaglandins in 4% of 
the patients. 
Follow-up times on the waiting list and waiting times to 
transplantation are presented in Table II. 
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Subgroups 
Subgroup with high-grade ventricular arrhythmias on 
Holter ECG. In 134 patients (21 with and 113 without 
ICD therapy) high-grade ventricular arrhythmias (cou- 
plets/triplets and/or ventricular arrhythmias ---4 consecu- 
tive complexes at a rate >-120/rain) were present on 
Holter ECG, which was done within 4 weeks before 
registration?' 11
Subgroup of survivors of sudden cardiac death. Before 
registration for transplantation 58 patients (21 with and 37 
without ICD therapy) had had an event of sudden cardiac 
death and were successfully resuscitated. Sudden cardiac 
death was classified by one or a combination of the 
following: the lack of worsening of the clinical setting 
within 1 hour before cardiac arrest, the need for external 
electric defibrillation for resuscitation, orECG documen- 
tation of life-threatening ventricular arrhythmias. 4 Docu- 
mented rhythm during cardiac arrest was ventricular 
fibrillation in 36 patients (62%), ventricular tachycardia n
20 patients (34%), and unknown in 2 patients (4%). In the 
majority of the 37 patients without ICD therapy, ICD 
therapy was avoided for nonmedical reasons (costs, n = 
16; referring centers refused use of ICDs, n = 8; ICD 
refused by the patient, n = 5) and in the minority of 
patients for medical reasons (worsening of the clinical 
setting after resuscitation,  = 2; intention to avoid 
thoracotomy in the elderly, n = 2; intention to await 
transplantation i  the hospital, n = 4). Patients with 
ventricular tachyarrhythmias during an episode of pump 
failure or after a new Q wave myocardial infarction were 
not included in this subgroup. 
Death on the waiting list: evaluation of circumstances. 
For evaluation of circumstances of death that occurred 
while the patient was on the waiting list, personal or 
telephone contact was made with the physicians of the 
patients or their family members. Sudden cardiac death 
while on the waiting list was defined as death occurring as 
a result of recurrent cardiac arrest or within 1 hour of the 
development of symptoms in a patient previously in stable 
condition or an unobserved death in a patient known to be 
in stable condition during the preceding 24 hours. Pump 
failure death while a patient was on the waiting list was 
defined as death as a result of one or more of the 
following: progressive heart failure, recurrent myocardial 
infarction, or preceding symptoms of more than 1 hour. 4 
Unknown death while a patient was on the waiting list was 
defined as an event for which there was no knowledge 
about circumstances. 
Statistical analysis. Comparisons between patients 
with and without ICD therapy were made by unpaired t 
test and X 2 analysis; level of significance was set at p -< 
0.05. 
In the Cox proportional hazards model, patients who 
did not die while on the waiting list were censored at the 
time of transplantation r at the last follow-up while on 
the waiting list at the end point of the study. Covariables 
used for calculation of independent predictors of mortal- 
ity were the absence of ICD therapy and baseline charac- 
teristics (Table I). All variables that reached statistical 
significance in univariate analysis entered stepwise multi- 
variate analysis. The estimation of relative risk and 95% 
confidence limits was calculated for each significant pre- 
dictor from the proportional hazard model. Cox propor- 
tional model analysis was done with BMDP statistical 
software, 1990 version (BMDP Statistical Software, Inc., 
Los Angeles, Calif.). 
Actuarial freedom from mortality while on the waiting 
list was calculated by Kaplan-Meier analysis with the use 
of SAS statistical software (SAS Institute Inc., CarT, N.C.). 
Results 
Baseline characteristics and follow-up. Detailed 
baseline characteristics of all study patients, of sub- 
groups, and of patients with ICDs are presented in 
Table I. 
All 228 study patients. Mean pulmonary vascular 
resistance was lower in the 21 patients with ICDs 
(1.8 Wood units) as compared with that in the 207 
patients without ICDs (2.8 Wood units). High-grade 
ventricular arrhythmias on Holter ECG occurred 
more frequently in the 21 patients with ICDs 
(100%) as compared with the frequency in the 207 
patients without ICDs (54.6%). Antiarrhythmic 
drug therapy was given to 6 of 21 patients with ICDs 
(30%), but only to 19 of 207 patients without ICDs 
(9.2%). 
Subgroup of l 34 patients with high-grade ventricular 
arrhythmias on Holter ECG. Mean cardiac index 
(2.3 L/rain per square meter) and mean pulmonary 
vascular esistance (1.8 Wood units) were better in 
the 21 patients with ICDs as compared with respec- 
tive values in the 113 patients without ICDs (mean 
cardiac index, 2.1 L/rain per square meter; mean 
pulmonary vascular esistance, 2.7 Wood units). 
Subgroup of 58 survivors of sudden cardiac death. 
There was no difference in baseline characteristics 
between the 21 patients with and the 37 patients 
without ICDs. 
In all 228 study patients and in the subgroups, 
follow-up times and waiting times to transplantation 
were comparable in patients with and without ICDs 
(Table II). 
Outcome. Outcomes of all 228 study patients, of 
subgroups, and of patients with ICD therapy are 
presented in Table III. 
The total mortality rate in all 228 study patients 
was 21.5%. Notably, within the whole study popula- 
tion and in the subgroup of patients with high-grade 
ventricular arrhythmias on Holter ECG sudden 
cardiac death occurred more frequently than death 
from pump failure. In the subgroup of survivors of 
sudden cardiac death, the most common event of 
death was pump failure. The mortality rate in 207 
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Fig. 1. Actuarial freedom from mortality in patients on waiting list. Line 1, 21 patients with ICD therapy; 
line 2, subgroup of survivors of sudden cardiac death (n = 58, including 21 patients with ICD therapy); line 
3, all study patients (n = 228, including 21 patients with ICD therapy); line 4, subgroup of patients with 
high-grade ventricular arrhythmias on Holter ECG (n = 134, including 21 patients with ICD therapy). 
Table III. {Outcome 
Subgroup of patients with 
high-grade ventricular Subgroup of survivors 
All study patients arrhythmias on Holter ECG of sudden cardiac Patients with ICD 
(n = 228) (n = 134) death (n = 58) therapy (n = 21) 
Death while on the waiting list (%) 49 (21.5) 
Sudden cardiac death (%) 28 (12.3) 
Pump failure death (%) 20 (8.8) 
Unknown cause of death (%) 1 (0.4) 
Still on the waiting list (%) 54 (23.7) 
Received transplantation (%) 125 (54.8) 
35 (26.1) 13 (22.4) 1 (4.7) 
19 (14.2) 6 (10.3) -- 
15 (11.2) 7 (12.1) 1 (4.7) 
1 (0.7) - -  - -  
26 (19.4) 12 (20.7) 6 (28.5) 
73 (54.5) 33 (56.9) 14 (66.7) 
patients without ICDs was 23.2% and the rate was 
4.7% in 21 patients with ICDs. 
The actuarial freedom from mortality while on 
the waiting list in all 228 study patients, subgroups, 
and patients with ICD therapy is shown in Fig. 1. 
ICD discharges during follow-up while the patient 
was on the waiting list occurred in 17 (80.9%) of the 
21 patients with ICDs. The median number of ICD 
discharges that occurred in those patients was 18.5 
(range 1: to 370). 
Cox propor t iona l  hazards  model. The significant 
predictors of mortality while patients were on the 
waiting list, relative risk, and 95% confidence limits 
are presented in Table IV. All presented variables 
were statistically significant in univariate analysis. 
Al l  study patients (n = 228). Stepwise multivariate 
survival analysis revealed that mortality was most 
powerfully predicted by central venous pressure 
(p < 0.0001), cardiac index (p = 0.002), and the 
absence of sinus rhythm (p = 0.035). The absence of 
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Table IV. Multivariate predictors of mortality in patients on the waiting list (Cox proportional hazards model) 
p Value Relative risk 95% confidence limits 
All study patients (n = 228) 
CVP <0.0001 
Cardiac index 0.002 
Absence of sinus rhythm 0.035 
Absence of ICD therapy 0.079 
Ventricular arrhythmias on Holter ECG 0.079 
Cause of heart failure 0.080 
Subgroup of patients with high-grade ventricular 
arrhythmias on Holter ECG (n = 134) 
Cardiac index 0.001 
CVP 0.014 
Absence of ICD therapy 0.022 
Absence of sinus rhythm 0.073 
Subgroup of survivors of sudden cardiac death (n = 58) 
Age 0.005 
Absence of ICD therapy 0.018 
1.1156 1.0698-1.1633 
0.4614 0.3257-0.6533 
1.7655 1.3059-2.3866 
5.4229 1.9428-15.1515 
1.7695 1.2718-2.4618 
1.6745 1.2498-2.2434 
0.4769 0.3159-0.7199 
1.1273 1.0701-1.1876 
5.1626 1.8467-14.4508 
1.8810 1.3182-2.6823 
1.1286 1.0703-1.1900 
6.6533 2.3474-18.8679 
Covariables u ed were baseline characteristics and the absence ofICD therapy (see Table I); all significant variables from univariate analysis entered stepwise 
multivariate analysis. CVP, Central venous pressure. 
ICD therapy (p = 0.079), the presence high-grade 
ventricular arrhythmias on Holter ECG (p = 0.079), 
and the cause of heart failure (p = 0.080) were 
marginally significant independent predictors of 
mortality. 
Subgroup of patients with high-grade ventricular 
arrhythmias on Holter ECG (n = 134). Death while 
patients were on the waiting list was strongly pre- 
dicted by cardiac index (p = 0.001), central venous 
pressure (p = 0.014), and the absence of ICD 
therapy (p = 0.022), whereas the absence of sinus 
rhythm was only marginally predictive (p = 0.073). 
Subgroup of survivors of sudden cardiac death (n = 
58). Age (p = 0.005) and the absence of ICD 
therapy Co = 0.018) were significant independent 
predictors of mortality. 
Antiarrhythmic therapy had no impact on mortal- 
ity in patients on the waiting list for all 228 patients 
and subgroups. 
Discussion 
In the cohort of 228 unselected, consecutive heart 
transplant candidates, ICD therapy had no impact 
on mortality while the patients were on the waiting 
list. However, in 134 patients with high-grade ven- 
tricular arrhythmias on Holter ECG and, particu- 
larly, in 58 patients with a history of sudden cardiac 
death ICD therapy had a significant impact on 
mortality. 
Within the study period 28 (12.3%) of 228 con- 
secutive patients died of sudden cardiac death while 
on the waiting list. In the 21 patients with ICDs 
there was no single event of sudden cardiac death. 
This suggests that the conventional indication for 
ICD therapy, that is, surviving an event of sudden 
cardiac death, seems ineffective to protect he entire 
population of heart transplant candidates. 6' s De- 
spite the safety and efficacy of ICDs in transplant 
candidates, 6-8 a more expanded, and therefore pro- 
phylactic, use of ICD therapy will remain a matter of 
discussion. The difficulties in identifying transplant 
candidates at risk for sudden cardiac death prospec- 
tively and the enormous cost (approximately 
$40,000 per device) of ICD devices force the critical 
design of ICD prophylaxis in transplant candidates. 
In the subgroup of 134 patients with high-grade 
ventricular arrhythmias on Holter ECG (including 
21 patients with ICDs) ICD therapy had a significant 
impact on mortality. We observed a 14.2% rate of 
sudden cardiac deaths and an overall mortality rate 
of 26.1%. The presence of high-grade ventricular 
arrhythmias on Holter ECG in advanced heart 
failure is an accepted predictor of cardiac mortali- 
ty.12, 13 A significant association of couplets/triplets 
or nonsustained ventricular tachycardia with in- 
creased risk of sudden cardiac death in patients with 
heart failure was recently shown; 14' 15 however, this 
still remains a matter of discussion) 6 High-grade 
ventricular arrhythmias may increase mortality by 
triggering life-threatening arrhythmias that either 
result in sudden cardiac death or in poorly tolerated 
hemodynamic ompromise and deterioration be- 
cause of pump failure) 7 ICDs detect and immedi- 
ately terminate ventricular arrhythmias and, there- 
fore, may not only prevent sudden cardiac death but 
also death from arrhythmia-induced pump failure) 7 
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Efficacy of ICD therapy in the termination of poten- 
tial life-threatening arrhythmias i reflected in the 
high incidence of (median 18.5) adequate ICD 
discharges in 17 of our 21 patients with ICDs during 
our short follow-up period. Our findings indicate 
that patients with high-grade ventricular arrhyth- 
mias on Holter ECG comprise a subpopulation at 
certain risk of sudden cardiac death while on the 
waiting list. Because heart transplant candidates 
with inducible ventricular arrhythmia on electro- 
physiologic stimulation have a significantly higher 
prevalence of lethal arrhythmic events, 18 expanded 
electrophysiologic stimulation could possibly be 
helpful in identifying patients who might receive 
potential benefit from prophylactic ICD bridge to 
transplantation. However, this has to be investigated 
by means of a prospective randomized study. 
Although not previously reported, it was not 
surprising to us that ICD therapy dramatically de- 
creased mortality in survivors of sudden cardiac 
death on the transplant waiting list. In this subgroup 
of 58 survivors of sudden cardiac death (including 21 
patients with ICDs) we observed a 10.3% rate of 
sudden cardiac deaths and an overall mortality rate 
of 22.4%. Although in this subpopulation the risk of 
early recurrence of lethal arrhythmia is significant, 19 
in our series pump failure death (12.1%) occurred 
more frequently than sudden cardiac death (10.3%). 
In severity of heart failure the 21 patients with ICDs 
were comparable to the 37 patients without ICDs at 
the time of registration (Table I). However, mortal- 
ity was strildngly lower in the ICD-treated patients 
with respect to sudden cardiac death and pump 
failure death. It can be doubted that all ICD dis- 
charges in 80.9% of our patients with ICDs (median 
18.5, up to 2170) treated ventricular tachycardias that 
were spontaneous in nature. Much more, follow-up 
on the waiting list revealed a marked correlation of 
ICD activity with worsening of ventricular function, 
as reported previously, s' 20 Therefore we speculate 
that the low number of pump failure deaths in our 
patients with ICDs does not mark patients with 
ICDs as "less sick," but we believe that immediate 
and consequent terminations of frequently occur- 
ring ventricular arrhythmias, which otherwise would 
have triggered hemodynamic deterioration, mark- 
edly supported prevention from pump failure death. 
ICD therapy was not given to 37 of the 58 survivors 
of sudden death, mainly because of nonmedical 
reasons uch as cost or refusal of ICD therapy by 
referring medical centers. The approaches of await- 
ing transplantation under close Holter monitoring 
out of the hospital and of awaiting transplantation in 
the hospital turned out not to be effective alterna- 
tives to ICD therapy. For this purpose, we believe 
that transplant candidates with a history of sudden 
cardiac death should receive ICD therapy whenever 
possible, even when waiting time to transplantation 
is expected to be short. 
The major aim of ICD therapy while a patient is 
on the waiting list for heart transplantation is short- 
term survival until transplantation. Under the as- 
sumptions of further limited availability of donor 
organs and a decreased mortality with prophylactic 
ICD therapy, waiting times to transplantation and 
time-dependent risk of deterioration caused by 
pump failure will increase for the patients. An 
overrepresentation f ICD therapy in transplant 
candidates will result in a great pool of patients with 
critical end-stage disease with severe pump failure, 5
which would finally negatively affect he outcome of 
the entire transplant program by increased periop- 
erative mortality after transplantation. 21 Further 
studies will be necessary to evaluate which percent- 
age of patients listed with ICD therapy optimizes 
overall survival for patients on the waiting list, 
without significant disadvantages for patients listed 
without ICDs. Therefore too enthusiastic use of 
prophylactic ICD therapy should be avoided. To 
optimize the cost-benefit ratio of short-term ICD 
bridge to transplantation, technology will have to 
focus on cheaper, simpler, or reusable devices. It 
seems likely that empiric use of amiodarone and 
sotalol in patients who are heart transplant candi- 
dates would be cheaper than ICD therapy and more 
suitable for expanded prophylaxis of lethal arrhyth- 
mias. 22 Studies on empiric use of amiodarone in 
advanced heart failure report effective suppression 
of ventricular arrhythmias; unfortunately this bene- 
ficial effect did not necessarily correlate with in- 
creased survival. 23' 24 As we calculated in multivari- 
ant analysis, therapeutic, that is, nonempiric, use of 
antiarrhythmic therapy with sotalol and amiodarone 
had no impact on mortality. It is hoped that ongoing 
work within the Congestive Heart Failure Survival 
Study of Antiarrhythmic Therapy will help to deter- 
mine benefit from prophylactic antiarrhythmic ther- 
apy. 25 
The study is limited by its retrospective d sign and 
the fact that ICD therapy was not randomly as- 
signed. Another major bias was that the low number 
of patients with ICD therapy resulted in discrepancy 
of sample sizes within the groups. The latter and 
differences in baseline characteristics of patients 
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with and without ICDs were corrected for influenc- 
ing factors by the Cox model used. Another poten- 
tial source of undetected bias is the high number of 
referring centers, which results in a variety of ap- 
proaches toward prevention and treatment of life- 
threatening ventricular arrhythmias. Another limi- 
tation of this study is the inability to exactly 
discriminate between tachyarrhythmia and electro- 
mechanical dissociation as the rhythm at the time of 
sudden cardiac arrest. 26 Finally, it has to be stated 
that this study only focused on a few months of 
events in patients on the heart transplant waiting 
list. Therefore the conclusions drawn in this study 
should not be extrapolated to long-term outcome of 
patients with heart failure. 
We conclude that ICD therapy should be given, 
whenever possible, to heart transplant candidates 
with a history of sudden cardiac death before regis- 
tration. For all other transplant candidates no rec- 
ommendations for prophylactic ICD bridge to trans- 
plant can be made. However, further studies hould 
clarify whether vigorous electrophysiologic stimula- 
tion in patients with high-grade ventricular arrhyth- 
mias on Holter ECG is helpful in identifying trans- 
plant candidates at risk for sudden cardiac death on 
the waiting list. 
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